Multi-omics data integration identifies novel biomarkers and patient subgroups in inflammatory bowel disease

António José Preto, Shaurya Chanana, Daniel Ence, Matt D Healy, Daniel Domingo-Fernández, Kiana A West
{"title":"Multi-omics data integration identifies novel biomarkers and patient subgroups in inflammatory bowel disease","authors":"António José Preto, Shaurya Chanana, Daniel Ence, Matt D Healy, Daniel Domingo-Fernández, Kiana A West","doi":"10.1101/2024.07.23.24310846","DOIUrl":null,"url":null,"abstract":"Objective: In this work, we explored one of the largest multi-omics cohorts in Inflammatory Bowel Disease (IBD), the Study of a Prospective Adult Research Cohort (SPARC IBD), with the goal of identifying predictive biomarkers for Crohn's Disease (CD) and Ulcerative Colitis (UC) and elucidating patient subtypes. Design: We analyzed genomics, transcriptomics (gut biopsy samples), and proteomics (blood plasma) from hundreds of patients from SPARC IBD. We trained a machine learning model that classifies UC vs. CD samples. In parallel, we leveraged multi-omics data integration to unveil patient subgroups in each of the two indications independently and analyzed the molecular phenotypes of these patient subpopulations.\nResults: The high performance of the model showed that multi-omics signatures are able to discriminate between the two indications. The most predictive features of the model, both known and novel omics signatures for IBD, can potentially be used as diagnostic biomarkers. Patient subgroups analysis in each indication uncovered omics features associated with disease severity in UC patients, and with tissue inflammation in CD patients. This culminates with the observation of two CD subpopulations characterized by distinct inflammation profiles.\nConclusion: Our work unveiled potential biomarkers to discriminate between CD and UC and to stratify each population into well-defined subgroups, offering promising avenues for the application of precision medicine strategies.","PeriodicalId":501258,"journal":{"name":"medRxiv - Gastroenterology","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.07.23.24310846","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: In this work, we explored one of the largest multi-omics cohorts in Inflammatory Bowel Disease (IBD), the Study of a Prospective Adult Research Cohort (SPARC IBD), with the goal of identifying predictive biomarkers for Crohn's Disease (CD) and Ulcerative Colitis (UC) and elucidating patient subtypes. Design: We analyzed genomics, transcriptomics (gut biopsy samples), and proteomics (blood plasma) from hundreds of patients from SPARC IBD. We trained a machine learning model that classifies UC vs. CD samples. In parallel, we leveraged multi-omics data integration to unveil patient subgroups in each of the two indications independently and analyzed the molecular phenotypes of these patient subpopulations. Results: The high performance of the model showed that multi-omics signatures are able to discriminate between the two indications. The most predictive features of the model, both known and novel omics signatures for IBD, can potentially be used as diagnostic biomarkers. Patient subgroups analysis in each indication uncovered omics features associated with disease severity in UC patients, and with tissue inflammation in CD patients. This culminates with the observation of two CD subpopulations characterized by distinct inflammation profiles. Conclusion: Our work unveiled potential biomarkers to discriminate between CD and UC and to stratify each population into well-defined subgroups, offering promising avenues for the application of precision medicine strategies.
多组学数据整合确定炎症性肠病的新型生物标记物和患者亚群
研究目的在这项研究中,我们探索了炎症性肠病(IBD)领域最大的多组学队列之一--前瞻性成人研究队列(SPARC IBD),目的是确定克罗恩病(CD)和溃疡性结肠炎(UC)的预测性生物标记物,并阐明患者亚型。设计:我们分析了数百名 SPARC IBD 患者的基因组学、转录组学(肠道活检样本)和蛋白质组学(血浆)。我们训练了一个机器学习模型来对 UC 与 CD 样本进行分类。与此同时,我们利用多组学数据整合技术揭示了这两种适应症各自独立的患者亚群,并分析了这些患者亚群的分子表型:该模型的高性能表明,多组学特征能够区分两种适应症。该模型最具预测性的特征,包括已知的和新的IBD组学特征,都有可能被用作诊断生物标志物。每个适应症的患者亚组分析发现了与 UC 患者疾病严重程度和 CD 患者组织炎症相关的全局组学特征。最终,我们观察到了两个以不同炎症特征为特征的 CD 亚群:我们的研究揭示了区分 CD 和 UC 的潜在生物标志物,并将两种人群划分为定义明确的亚组,为精准医疗策略的应用提供了前景广阔的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信